Drugmaker Settles Qui Tam Claims for $26.7 Million

Novo Nordisk will pay $25 million to the U.S. Government to settle allegations of improper marketing of the anti-clotting drug NovoSeven. The complaint alleged that the company improperly promoted NovoSeven for indications not approved by the Food and Drug Administration.

Novo Nordisk also agreed to pay $1.725 million to the U.S. Government and four states to resolve allegations that its sales representatives paid Rite Aid pharmacists to recommend the diabetes drugs Novolin and Novolog.

Novo Nordisk made no admission of wrongdoing in either settlement.

Posted in Anti-Kickback Statute, False Claims, Off-Label Marketing, SettlementsNo Comments


Leave a Reply

This blog is designed to provide general information only. This information is not and should not be construed to be legal advice. The transmission of the information found on this blog also does not result in the formation of a lawyer-client relationship.

Copyright 2014 Berg & Androphy.